Ashley Mason
Osher Center for Integrative Medicine at UCSF
Ashley Mason is a clinical psychologist and the director of the Sleep, Eating, and Affect Laboratory at the Osher Center for Integrative Medicine at UCSF. Her research focuses on non-pharmacological treatments for depression, insomnia, and eating behaviors, including cognitive behavioral therapy and whole-body hyperthermia. Additionally, her published work examines the application of wearable device metrics to analyze sleep, body temperature dynamics, and physiological health.
31 claims checked on air: 2 context 1 overstated 27 supported 1 unverified
What they said on air
2 citing their own research
A 2016 randomized controlled trial by Janssen et al. showed that a single session of whole-body hyperthermia significantly reduced depression symptoms within one week, with the effect maintained across six weeks.
"So in 2016 this paper came out by Janssen and a bunch of other co-authors where they reported on a whole-body hyperthermia protocol that they had used to test as a treatment for clinical depression... The drops in depression within a week were pretty impressive, and what's more, those drops were maintained six weeks later. And this was one whole-body hyperthermia session." (said at 0:03:55)
A 2016 double-blind, sham-controlled randomized clinical trial by Janssen et al. evaluated the effect of a single session of whole-body hyperthermia (WBH) versus a sham heating procedure in 30 unmedicated adults with major depressive disorder. Depressive symptoms on the 17-item Hamilton Depression Rating Scale were significantly lower in the active WBH group compared with the sham group at week 1 (-6.53 points; 95% CI, -9.90 to -3.16; P < .001) and remained significantly reduced throughout the 6-week follow-up period (week 6: -4.27 points; 95% CI, -7.94 to -0.61; P = .02). Certainty is moderate due to the small sample size (n = 30 randomized).
- supports: Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder: A Randomized Clini… (JAMA psychiatry 2016) · cited 153x in the literature
"When compared with the sham group, the active WBH group showed significantly reduced Hamilton Depression Rating Scale scores across the 6-week postintervention study period (WBH vs sham; week 1: -6.53, 95% CI, -9.90 to -3.16, P < .001; week 2: -6.35, 95% CI, -9.95 to -2.74, P = .001; week 4: -4.50, 95% CI, -8.17 to -0.84, P = .02; and week 6: -4.27, 95% CI, -7.94 to -0.61, P = .02)." (abstract, results, passage verified)
pubmedfull study (doi)
In the Janssen 2016 whole-body hyperthermia protocol for depression, participants were heated until reaching a core body temperature of 38.5 °C, after which heating was turned off and core temperature continued rising to approximately 38.85 °C during a one-hour cool-down period.
"these people who were randomized to receive whole-body hyperthermia went into this sauna tent, if you will, the Heckel machine, and they were heated until they reached a core body temperature of 38.5 degrees Celsius. After that time, the sauna was turned off and they stayed in there anyway for another hour, just lying there, and during that time their temperature actually continued to rise all the way up to about 38.85 or so degrees Celsius." (said at 0:03:55)
The statement accurately describes the protocol used in the 2016 randomized clinical trial by Janssen et al. (JAMA Psychiatry). In the trial, participants with major depressive disorder randomized to active whole-body hyperthermia used a Heckel infrared hyperthermia device (Heckel HT3000) and were heated until reaching a target core body temperature of 38.5 °C. After active heating was ceased, participants remained in the device for a 60-minute retention/cool-down period, during which thermal inertia caused core body temperature to continue rising, reaching a mean peak of approximately 38.85 °C.
In the 2016 Janssen whole-body hyperthermia trial, approximately 71% of participants in the sham control condition believed they had received the active whole-body hyperthermia treatment.
"Some 71% of people in that control condition thought they got the actual sauna treatment." (said at 0:05:20)
In the 2016 randomized clinical trial by Janssen et al. investigating whole-body hyperthermia (WBH) for major depressive disorder, the sham procedure successfully blinded the majority of participants: immediately following the intervention, 10 of 14 participants (71.4%) randomized to the sham control condition believed they had received the active WBH treatment.
Hyperhidrosis (excessive sweating) is one of the most common side effects of SSRI antidepressants.
"and it turns out that one of the most common side effects of SSRIs is hyperhidrosis, it's sweating." (said at 0:09:11)
Published clinical literature recognizes hyperhidrosis (excessive sweating) as a well-documented and common adverse effect of selective serotonin reuptake inhibitors (SSRIs) and other second-generation antidepressants. Studies report an incidence of antidepressant-induced excessive sweating ranging from approximately 5% to 22% among treated patients.
- supports: Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. (Drug safety 2008) · cited 158x in the literature
"Drugs that induce hyperhidrosis, or sweating in excess of that needed to maintain thermoregulation, can cause patient discomfort and embarrassment, and include cholinesterase inhibitors, selective serotonin reuptake inhibitors, opioids and tricyclic antidepressants." (abstract, passage verified)
pubmedfull study (doi) - supports: Antidepressant-induced excessive sweating: clinical features and treatment with terazosin. (Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 2013) · cited 13x in the literature
"Antidepressant-induced excessive sweating (ADIES) occurs in 5% to 14% of patients taking antidepressants, usually persists throughout treatment, and causes subjective distress and functional impairment." (abstract, background, passage verified)
pubmed - supports: Clinical practice guideline for primary care providers in the management of antidepressant… (Journal of the American Association of Nurse Practitioners 2020) · cited 2x in the literature
"Antidepressant-induced excessive sweating (ADIES) is a side effect that occurs in approximately 22% of patients taking antidepressant medications and can negatively affect patient medication adherence." (abstract, background, passage verified)
pubmedfull study (doi)
Studies published by Dr. Avery in the 1980s and 1997 demonstrated that individuals with depression often exhibit elevated nighttime body temperature and impaired thermoregulatory cooling.
"Well, it turns out there is literature showing temperature dysregulation in people with depression back early 1980, '82, and then '97. A researcher, Dr. Avery, published some work showing that people with depression often have higher nighttime body temperatures and they're not as good at thermoregulatory cooling, they don't sweat as much to cool themselves down." (said at 0:10:40)
The speaker bundles two distinct claims regarding the research by Dr. David H. Avery: (1) that depressed individuals have elevated nocturnal body temperature and altered circadian temperature rhythms, and (2) that they fail to cool down due to reduced sweating. Small comparative studies by Avery and colleagues (1982, 1986, 1997, 1999) did observe significantly higher nocturnal core body temperatures and circadian phase delays in depressed patients compared to controls. However, when Avery et al. directly investigated nocturnal sweating in 1999, they found that nocturnal sweat rates in depressed patients did not differ significantly from healthy controls, concluding that impaired sweating was not the mechanism driving elevated nocturnal body temperatures.
A published paper showed that successful electroconvulsive therapy (ECT) treatment for depression is accompanied by a reduction in patients' core body temperature.
"There is a paper that showed that with successful ECT treatment, the patients' temperatures dropped alongside their depression." (said at 0:11:15)
A published clinical study by Szuba and colleagues (1997) evaluated core body temperature across 24-hour cycles before and after electroconvulsive therapy (ECT) in patients with major depression compared to healthy controls. The study found that elevated baseline 24-hour and sleep core body temperatures significantly decreased following a course of ECT, normalizing to levels seen in healthy controls alongside clinical improvement. Evidence is rated as low certainty due to the very small sample size (n=6 per group) and subsequent conflicting reports using peripheral oral temperature measurements.
In a 2013 open-label study by Hanusch et al., the decrease in core body temperature measured over five days following whole-body hyperthermia was correlated with a reduction in depression scores.
"And from that Hanusch paper, that single-arm sauna trial, what they found was that the decrease in body temperature was correlated with a decrease in depression, and they measured that decrease in body temperature pretty carefully: they were using an indwelling rectal probe. So they were really measuring it those five days afterward." (said at 0:11:30)
In an open-label pilot investigation published in 2013 (Hanusch et al., Am J Psychiatry), researchers administered whole-body hyperthermia to individuals with major depression and tracked core body temperature and depressive symptoms, finding that post-treatment thermoregulatory cooling was associated with reduced depression ratings. Subsequent randomized controlled trials (such as Janssen et al., 2016) confirmed significant antidepressant effects of whole-body hyperthermia compared to a sham control. Because the original Hanusch study was an uncontrolled open-label trial with a small sample size, the overall certainty for the specific correlation observed in that initial dataset is low.
In clinical trials of whole-body hyperthermia for depression, heating sessions lasted approximately 107 minutes on average in the Janssen protocol and two hours in the Hanusch protocol.
"In these protocols, the Janssen protocol and the Hanusch protocol, people were in the sauna for well over an hour—two hours in the Hanusch case, and I think 107 minutes on average in the Janssen paper." (said at 0:22:15)
The clinical trial led by Janssen et al. (2016) evaluated whole-body hyperthermia (WBH) using a specific heating protocol (Heckel HT3000 device) in patients with major depressive disorder, where active heating took approximately 107 minutes on average to reach the target core body temperature of 38.5°C before a cooling-down phase. Similarly, clinical protocols for mild-to-moderate WBH (such as those studied by Hanusch and colleagues using thermal baths or infrared WBH devices) typically involve heating and heat-retention sessions lasting around two hours in total. However, these clinical trials utilized specialized whole-body hyperthermia devices or hot water immersion under medical supervision, not traditional saunas.
A review by Janssen and Raison found that whole-body hyperthermia protocols with a longer duration spent reaching peak body temperature showed larger effect sizes in depression score reduction.
"in a recent paper that actually incidentally Janssen and Raison had written together, they reviewed some of the studies that exist looking at whole-body hyperthermia for depression. And one of the things they noted is that the effect sizes of the change in depression from before to after the intervention—in other words, the size of the reduction in depression—was higher if people spent more time getting to that peak temperature." (said at 0:27:13)
No published record matching a review by Janssen and Raison that found whole-body hyperthermia protocols with longer durations spent reaching peak body temperature produce larger effect sizes in depression score reduction was located; this does not prove the claim false. While Janssen, Raison, and colleagues have published trials demonstrating the antidepressant effects of whole-body hyperthermia (such as JAMA Psychiatry 2016), an indexed review specifically analyzing effect sizes as a function of the rate or duration of heating to peak temperature was not found.
Cardiovascular disease and depression frequently co-occur as comorbidities.
"cardiovascular disease and depression, those often happen together." (said at 0:32:50)
Cardiovascular disease and depression demonstrate robust, bidirectional co-occurrence across epidemiological and clinical studies. Systematic reviews and meta-analyses consistently confirm that individuals with depression have a significantly elevated risk of developing cardiovascular events (such as myocardial infarction), while patients with established cardiovascular disease experience high rates of subsequent comorbid depression.
Exercise has been shown to increase brain-derived neurotrophic factor (BDNF).
"It's one of the things that exercise has been shown to increase, and it's a thought that may help with neuroplasticity, right?" (said at 0:35:21)
Extensive systematic reviews and meta-analyses of randomized controlled trials demonstrate that both acute exercise bouts and regular exercise training significantly increase circulating levels of brain-derived neurotrophic factor (BDNF). A 2026 meta-analysis of acute cardiovascular exercise trials confirmed a statistically significant, moderate increase in circulating BDNF (pooled Hedges' g = 0.48, 95% CI [0.29, 0.68]), especially with moderate-to-vigorous exercise. Similarly, a 2025 meta-analysis of 35 randomized controlled trials in older adults found that chronic exercise training significantly increases resting BDNF levels across aerobic, resistance, and combined modalities (SMD = 0.56, 95% CI [0.28, 0.85]).
Depression has an inflammatory component in some individuals, as documented in Dr. Charles Raison's 2007 paper 'Cytokines Sing the Blues'.
"dating back to Dr. Charles Raison's paper in 2007 called "Cytokines Sing the Blues" looking at how depression may be quite inflammatory, right, for some people who have it." (said at 0:35:21)
The claim accurately describes Dr. Charles Raison and colleagues' influential review titled 'Cytokines sing the blues: inflammation and the pathogenesis of depression' (published in Trends in Immunology in 2006). The paper synthesized growing evidence demonstrating that inflammatory responses and elevated proinflammatory cytokines play a significant role in the pathophysiology of depression in a subset of patients.
Exercise induces a temporary acute inflammatory response that leads to beneficial adaptive anti-inflammatory changes.
"we know that exercise is temporarily inflammatory when you do it, but it's actually in a good way because of the adaptive changes that follow from that." (said at 0:35:21)
Acute bouts of exercise induce a transient elevation in cytokines and myokines (such as interleukin-6, IL-8, and tumor necrosis factor-alpha), which in turn stimulate the release of potent anti-inflammatory mediators (such as IL-10 and IL-1 receptor antagonist) and inhibit pro-inflammatory signaling. Repeated exercise stimuli drive chronic adaptive anti-inflammatory effects and reduce basal systemic inflammation.
Cognitive behavioral therapy is considered a gold standard and first-line treatment for depression.
"Cognitive behavioral therapy is a psychotherapy used for depression. It's considered gold standard. It's a first-line treatment for depression." (said at 0:36:23)
Cognitive behavioral therapy (CBT) is widely recognized as a gold-standard psychotherapy and recommended as a first-line intervention for major depressive disorder across major clinical guidelines (such as NICE and APA). Extensive systematic reviews and network meta-analyses of hundreds of randomized controlled trials confirm that CBT—delivered individually, in groups, or in combination with pharmacotherapy—is an efficacious first-line treatment for both mild and moderate-to-severe depression.
- supports: A systematic review and network meta-analysis of psychological, psychosocial, pharmacologi… (EClinicalMedicine 2024) · cited 24x in the literature
"We aimed to identify the most effective first-line treatments for new episodes of less and more severe depression (defined by depression scale cut-off scores), to update NICE guidance on the management of Depression in Adults in England... Group CT/CBT (and possibly group yoga and self-help) appears efficacious in less severe depression, whereas antidepressants do not show evidence of effect. Combined antidepressants with individual CT/CBT, acupuncture and, possibly, group exercise, individual psychological therapies (behavioural therapies, CT/CBT) alone, and antidepressants alone appear efficacious in more severe depression." (abstract, aims and conclusions, passage verified)
pubmedfull study (doi)
Reviews and meta-analyses show that cognitive behavioral therapy is effective for depression.
"there's reviews, meta-analyses showing that cognitive behavioral therapy for depression works." (said at 0:40:26)
Extensive systematic reviews and meta-analyses encompassing hundreds of randomized controlled trials demonstrate that cognitive behavioral therapy (CBT) is an effective treatment for major depression in adults, yielding moderate to large effect sizes when compared to control conditions.
- supports: Five decades of research on psychological treatments of depression: A historical and meta-… (The American psychologist 2025) · cited 37x in the literature
"Cognitive behavior therapy (CBT) is by far the best examined type of therapy (52%), but not necessarily more effective than other therapies. [...] The evidence that psychotherapies are effective is strong and growing every year." (abstract, results)
pubmedfull study (doi) - supports: Cognitive Behavior Therapy for Mental Disorders in Adults: A Unified Series of Meta-Analys… (JAMA psychiatry 2025) · cited 56x in the literature
"In this unified series of meta-analyses, CBT was probably effective in the treatment of mental disorders, including major depression, anxiety disorders, PTSD, OCD, and eating disorders, and possibly effective in psychotic and bipolar disorders." (abstract, conclusions, passage verified)
pubmedfull study (doi)
A 2017 study found that hot bath sessions improved depressive symptoms at two weeks, with the symptom reduction fading somewhat by four weeks.
"there was a 2017 paper with hot baths, and they did see that two weeks out that they had improved those symptoms, but the reduction had faded some by four weeks." (said at 0:44:28)
A 2017 randomized, sham-controlled pilot trial (n = 36) tested the effects of two hyperthermic baths (40 °C) per week for 4 weeks against a sham green-light intervention in outpatients with moderate depressive disorder. The study found a statistically significant reduction in Hamilton Depression Rating Scale (HAM-D) scores in the hyperthermic bath group compared to the control group at 2 weeks (after 4 interventions), with treatment effects attenuating somewhat over longer follow-up.
- supports: Effects of hyperthermic baths on depression, sleep and heart rate variability in patients … (BMC complementary and alternative medicine 2017) · cited 51x in the literature
"Medically stable outpatients with confirmed depressive disorder (ICD-10: F32/F33) who were moderately depressed as determined by the 17-item Hamilton Scale for Depression (HAM-D) score ≥18 were randomly assigned to 2 hyperthermic baths (40 °C) per week for 4 weeks or a sham intervention with green light and follow-up after 4 weeks. Main outcome measure was the change in HAM-D total score from baseline (T0) to the 2-week time point (T1). A total of 36 patients were randomized (hyperthermic baths, n = 17; sham condition, n = 19). The intention-to-treat analysis showed a significant (P = .037) difference in the change in HAM-D total score with 3.14 points after 4 interventions (T1) in favour of the hyperthermic bath group compared to the placebo group." (abstract, methods and results, passage verified)
pubmedfull study (doi)
Population chronotypes are roughly distributed as one-third morning types, one-third evening types, and one-third intermediate types.
"I think the data are that it's kind of roughly a third, a third, a third-ish: a third of people are morning people, a third-ish of people are evening people, and then a third-ish are somewhere in the middle." (said at 0:47:06)
Population chronotypes are continuously distributed along a normal (near-Gaussian) curve rather than divided into equal thirds. Consequently, intermediate (neither morning nor evening) types make up the largest proportion of the population—typically around 50% or more depending on the scoring criteria and age group—while clear morning and evening types represent smaller proportions (often ~10–25% each under modernized cutoffs, or heavily skewed toward morning types with age under traditional Horne-Östberg criteria).
- partial: The epidemiology of morningness/eveningness: influence of age, gender, ethnicity, and soci… (Journal of biological rhythms 2006) · cited 379x in the literature
"According to the Horne and Ostberg classification, 49.8% of the total population was classified as morning type compared to 5.6% having an evening-type preference. However, using new cutoffs for middle-aged working adults described by Taillard et al. (2004), 24.7% of the population was morning type and 26.4% was evening type." (abstract, results, passage verified)
pubmedfull study (doi) - context: Epidemiology of the human circadian clock. (Sleep medicine reviews 2007) · cited 1554x in the literature
"Sleep and wake times show a near-Gaussian distribution in a given population, with extreme early types waking up when extreme late types fall asleep." (abstract, passage verified)
pubmedfull study (doi)
Having an evening chronotype (being a night owl) is associated with increased health risks compared to having a morning chronotype.
"A chronotype isn't necessarily a sleep problem. It poses more health risks for night owls, but insomnia is something different altogether." (said at 0:48:03)
Large-scale observational cohort studies and meta-analyses consistently show that an evening chronotype (being a "night owl") is associated with increased health risks compared to a morning chronotype. A systematic review and meta-analysis of observational studies encompassing over 370,000 individuals found that evening chronotypes had significantly worse cardiometabolic profiles (higher blood glucose, HbA1c, LDL cholesterol, and triglycerides) and elevated risks of type 2 diabetes (OR 1.30), cancer (OR 1.18), and depression (OR 1.86). In a prospective UK Biobank cohort of over 433,000 adults, definite evening types exhibited higher prevalences of psychological, metabolic, neurological, and respiratory disorders, along with a 10% higher risk of all-cause mortality (HR 1.10) compared to definite morning types.
- supports: Associations between chronotype, morbidity and mortality in the UK Biobank cohort. (Chronobiology international 2018) · cited 274x in the literature
"Comparing definite evening type to definite morning type, the associations were strongest for psychological disorders (OR 1.94, 95% CI 1.86-2.02, p = < 0.001), followed by diabetes (OR 1.30, 95% CI 1.24-1.36, p = < 0.001), neurological disorders (OR 1.25, 95% CI 1.20-1.30, p = < 0.001), gastrointestinal/abdominal disorders (OR 1.23, 95% CI 1.19-1.27, p = < 0.001) and respiratory disorders (OR 1.22, 95% CI 1.18-1.26, p = < 0.001)... Compared to definite morning types, definite evening types had significantly increased risk of all-cause mortality (HR 1.10, 95% CI 1.02-1.18, p = 0.012)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Chronotype Differences in Energy Intake, Cardiometabolic Risk Parameters, Cancer, and Depr… (Advances in nutrition (Bethesda, Md.) 2022) · cited 108x in the literature
"By comparing morning and evening subjects, pooled analyses of cross-sectional studies showed significantly (P < 0.001) higher concentrations of blood glucose [mean difference (MD): 7.82; 95% CI: 3.18, 12.45], glycated hemoglobin (MD: 7.64; 95% CI: 3.08, 12.21), LDL cholesterol (MD: 13.69; 95% CI: 6.84, 20.54), and triglycerides (MD: 12.62; 95% CI: 0.90, 24.35) in evening subjects. Furthermore, an association between evening type and the risk of diabetes (OR: 1.30; 95% CI: 1.20, 1.41), cancer (OR: 1.18; 95% CI: 1.08, 1.30), and depression (OR: 1.86; 95% CI: 1.20, 2.88) was reported." (abstract, results, passage verified)
pubmedfull study (doi)
Between 28% and 45% of insomnia susceptibility is attributable to genetics.
"there's some genetics to it, like 28 to 45% of insomnia is genetic." (said at 0:48:06)
Twin studies and quantitative genetic meta-analyses consistently find that the heritability of insomnia disorder and insomnia-related symptoms falls in the ~30% to 45% range (with a systematic meta-analysis of twin studies finding an overall meta-analytic heritability estimate of 40%).
Clinical insomnia is defined by difficulty initiating, maintaining sleep, or waking early at least three nights per week for at least three months, accompanied by distress.
"And insomnia is really difficulty falling asleep, difficulty staying asleep, or difficulty with waking up too early in the morning and not being able to get back to sleep, for this to be happening at least three nights or so a week, for it to have been going on for at least three months, and for it to be distressing." (said at 0:48:37)
The speaker accurately recites the core diagnostic criteria for chronic insomnia disorder as established in standard psychiatric and sleep medicine classification systems, including the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) and ICSD-3 (International Classification of Sleep Disorders, Third Edition). Under these criteria, insomnia disorder requires reported difficulty initiating sleep, maintaining sleep, or early-morning awakening with inability to return to sleep, occurring at least 3 nights per week, persisting for at least 3 months, and causing clinically significant distress or daytime impairment.
Taking long daytime naps reduces accumulated homeostatic sleep drive needed to fall asleep and stay asleep at night.
"Well, guess what? If you're taking long naps during the day, you're decreasing the sleep drive that you have at the end of the day that helps capitulate you into sleep and keep you asleep." (said at 0:53:03)
The claim is supported by human experimental sleep research and the well-established two-process model of sleep regulation. Homeostatic sleep pressure (Process S) accumulates during continuous wakefulness and dissipates during sleep, as tracked neurophysiologically by electroencephalographic slow-wave activity/energy. Randomized controlled trials demonstrate that daytime naps discharge homeostatic sleep pressure, leading to longer sleep latency, decreased sleep efficiency, and reduced slow-wave energy during subsequent nocturnal sleep.
Dismantling studies of Cognitive Behavioral Therapy for Insomnia (CBT-I) show that sleep restriction and stimulus control are the most critical components for achieving positive outcomes.
"what we know from studies that have been termed dismantling studies, where they've taken this whole intervention and they've taken it apart and they've seen, well, which pieces are most important for good outcomes, we know that the pieces that are really important are the sleep restriction part—matching the amount of time that you're in bed to the amount of time that you can actually sleep—and also the stimulus control" (said at 1:03:58)
Component network meta-analyses and dismantling randomized controlled trials of Cognitive Behavioral Therapy for Insomnia (CBT-I) consistently demonstrate that behavioral components—specifically sleep restriction therapy and stimulus control therapy—are the primary active drivers of improvement in insomnia severity and sleep continuity parameters (such as sleep efficiency, sleep onset latency, and wake after sleep onset), whereas components such as sleep hygiene education and relaxation techniques provide negligible or non-significant independent benefits.
- supports: Components and Delivery Formats of Cognitive Behavioral Therapy for Chronic Insomnia in Ad… (JAMA psychiatry 2024) · cited 157x in the literature
"Results suggested that critical components of CBT-I are cognitive restructuring (remission incremental odds ratio [iOR], 1.68; 95% CI, 1.28-2.20) third-wave components (iOR, 1.49; 95% CI, 1.10-2.03), sleep restriction (iOR, 1.49; 95% CI, 1.04-2.13), and stimulus control (iOR, 1.43; 95% CI, 1.00-2.05). Sleep hygiene education was not essential (iOR, 1.01; 95% CI, 0.77-1.32), and relaxation procedures were found to be potentially counterproductive(iOR, 0.81; 95% CI, 0.64-1.02)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Network meta-analysis examining efficacy of components of cognitive behavioural therapy fo… (Clinical psychology review 2024) · cited 37x in the literature
"For the primary outcome insomnia severity, a significant positive effect for sleep restriction therapy (d = -0.45; 95 % CI: [-0.63; -0.36]) was found. Overall, the results suggest that sleep restriction therapy improves self-reported sleep continuity and sleep quality, and stimulus control therapy improves self-reported and objective total sleep time. No significant effects of psychoeducation, relaxation therapy, and cognitive therapy, and no further significant effects of any CBT-I component on objective sleep parameters were found... The current results suggest that sleep restriction therapy and stimulus control therapy are the most effective components of CBT-I." (abstract, results, passage verified)
pubmedfull study (doi)
The lowest commercially available dose of standard immediate-release Ambien (zolpidem) is 5 mg.
"I think the smallest Ambien you can get is five milligrams." (said at 1:07:30)
Standard immediate-release oral formulations of brand-name Ambien (zolpidem tartrate) are manufactured in 5 mg and 10 mg tablet strengths, making 5 mg the lowest commercially available dose for the standard immediate-release tablet. Lower-dose formulations exist only as alternative sublingual products (such as 1.75 mg and 3.5 mg sublingual tablets indicated specifically for middle-of-the-night awakening), whereas the standard extended-release formulation (Ambien CR) is available in 6.25 mg and 12.5 mg strengths.
The U.S. Department of Veterans Affairs developed a publicly available mobile application called Insomnia Coach for cognitive behavioral therapy for insomnia.
"There's Insomnia Coach, which I think is maybe still free. I think the VA actually put one out that anybody can use, and that's in Google Play and iTunes stores." (said at 1:12:02)
The U.S. Department of Veterans Affairs (VA), via the National Center for PTSD, developed and maintains a suite of publicly available, free mobile applications for sleep and mental health, including Insomnia Coach (a self-guided app based on Cognitive Behavioral Therapy for Insomnia) and CBT-I Coach, available on major mobile platforms such as Google Play and the Apple App Store.
- supports: VA mobile apps for PTSD and related problems: public health resources for veterans and tho… (mHealth 2018) · cited 76x in the literature
"Many public health agencies, including the U.S. Department of Veterans Affairs (VA), have identified the use of mobile technologies as an essential part of a larger strategy to address major public health challenges. The VA's National Center for PTSD (NCPTSD), in collaboration with VA's Office of Mental Health and Suicide Prevention and the Defense Health Agency inside the U.S. Department of Defense (DoD), has been involved in the development, evaluation, and testing of 15 mobile apps" (abstract, background, passage verified)
openalexfull study (doi) - supports: Training Staff Across the Veterans Affairs Health Care System to Use Mobile Mental Health … (JMIR Mental Health 2023) · cited 10x in the literature
"The National Center for PTSD, within the Department of Veterans Affairs (VA), has developed a suite of free, publicly available, evidence-informed apps that can reach an increasing number of veterans and bridge gaps in care by providing resources to those who are not engaged in mental health treatment." (abstract, background, passage verified)
openalexfull study (doi)
The American College of Physicians established that Cognitive Behavioral Therapy for Insomnia (CBT-I) should be the first-line treatment for insomnia before sleep medications are prescribed.
"the American College of Physicians did say that this should be the first-line treatment for insomnia before a medication for sleep problems is prescribed" (said at 1:12:30)
In its 2016 clinical practice guideline on the management of chronic insomnia disorder in adults, the American College of Physicians (ACP) issued a strong recommendation that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial (first-line) treatment. Pharmacological therapy was recommended only via shared decision-making as an add-on option for adults in whom CBT-I alone was unsuccessful.
- supports: Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the … (Annals of internal medicine 2016) · cited 1986x in the literature
"ACP recommends that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder. (Grade: strong recommendation, moderate-quality evidence). Recommendation 2: ACP recommends that clinicians use a shared decision-making approach, including a discussion of the benefits, harms, and costs of short-term use of medications, to decide whether to add pharmacological therapy in adults with chronic insomnia disorder in whom cognitive behavioral therapy for insomnia (CBT-I) alone was unsuccessful. (Grade: weak recommendation, low-quality evidence)." (abstract, recommendations, passage verified)
pubmedfull study (doi)
A randomized study comparing CBT-I, tai chi, and a sleep seminar showed that CBT-I led to the largest reductions in hs-CRP and improvements in sleep lasting up to 16 months.
"shows how people's C-reactive or hs-CRP changes during treatment compared—it's like tai chi versus a sleep seminar versus cognitive behavioral therapy for insomnia. Everyone got one of those three. And what they show is 16 months out, the people who got the CBT-I had the greatest reductions in their hs-CRP and the biggest improvements in their sleep, lasting all the way out to 16 months, and treatment only occurred in the first two months." (said at 1:13:08)
A randomized controlled comparative efficacy trial in 123 older adults with chronic insomnia (Irwin et al., 2014, 2015) evaluated weekly 2-hour sessions of cognitive behavioral therapy for insomnia (CBT-I), Tai Chi Chih (TCC), or a sleep seminar (SS) active control. At 16-month follow-up, CBT-I led to significantly greater and sustained improvements in clinical insomnia remission, sleep quality, and parameters compared to TCC and SS. Furthermore, CBT-I was uniquely associated with sustained reductions in high-sensitivity C-reactive protein (hs-CRP) levels and a significantly lower risk of elevated CRP (>3.0 mg/L) at 16 months compared to the control group (OR 0.26, p < 0.05). The only minor discrepancy in the spoken details is that the active intervention duration was 4 months (16 weeks) rather than 2 months.
- supports: Cognitive behavioral therapy vs. Tai Chi for late life insomnia and inflammatory risk: a r… (Sleep 2014) · cited 299x in the literature
"CBT performed better than TCC and SS in remission of clinical insomnia as ascertained by a clinician (P < 0.01), and also showed greater and more sustained improvement in sleep quality, sleep parameters, fatigue, and depressive symptoms than TCC and SS (all P values < 0.01). As compared to SS, CBT was associated with a reduced risk of high CRP levels (> 3.0 mg/L) at 16 months (odds ratio [OR], 0.26 [95% CI, 0.07-0.97] P < 0.05)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Cognitive behavioral therapy and tai chi reverse cellular and genomic markers of inflammat… (Biological psychiatry 2015) · cited 228x in the literature
"As compared with sleep seminar education active control condition, CBT-I reduced levels of CRP (months 4 and 16, ps < .05), monocyte production of proinflammatory cytokines (month 2 only, p < .05), and proinflammatory gene expression (month 4, p < .01)." (abstract, results, passage verified)
pubmedfull study (doi)
Neuroimaging studies of experienced meditators demonstrate changes in brain pattern activation during meditation.
"Dr. Judson Brewer has done a bunch of work on looking at actual brain activation in meditators and how during meditation their brain pattern activation can actually change." (said at 1:17:27)
Neuroimaging research led by Judson Brewer and colleagues has demonstrated that experienced meditators exhibit distinct changes in brain activation and functional connectivity during meditation. Using functional magnetic resonance imaging (fMRI), these studies showed significant deactivation in key nodes of the default mode network (DMN)—particularly the medial prefrontal cortex and posterior cingulate cortex—across various meditation practices (such as concentration, loving-kindness, and choiceless awareness) when compared to meditation-naive controls or active cognitive tasks.
A clinical trial of a mindful eating intervention among overweight women significantly reduced eating in response to cravings.
"Jud and I actually did a trial together where we did a mindful eating intervention for people who said they have way too many cravings that they eat in response to, and these were, the sample was all overweight women. And we gave them this intervention where they had to get curious about their actual behavior, they had to slow down, eat mindfully, and really look at what is the true reward of what they're doing. And we found that people ate in response to their cravings a whole lot less after doing this training." (said at 1:17:55)
A proof-of-concept clinical trial conducted by Mason, Brewer, and colleagues evaluated a 28-day smartphone-delivered mindful eating intervention among 104 adult women with overweight or obesity (mean BMI 31.5 kg/m²). Using ecological momentary assessment, the study found a statistically significant 40.21% reduction in craving-related eating from pre-intervention to one-month post-intervention (p < 0.001), alongside significant reductions in trait food cravings. Certainty is rated low due to the uncontrolled, single-arm study design.
Banning the sale of sugar-sweetened beverages across a workplace campus combined with a brief motivational intervention led to reduced soda consumption over time.
"Dr. Elissa Epel and I published a paper a while ago showing that if you ban the sale of sugary beverages, which we did at UCSF all over the campus, and then you also give people a brief motivational intervention where you show them here's how many sugar cubes are in all the Coke you're drinking on a daily basis, and you give them some information that's kind of this brief motivational interviewing-type stuff, these folks will drink less soda over time." (said at 1:18:56)
The speaker accurately describes a published study conducted by their research team at the University of California, San Francisco (UCSF). The study evaluated the impact of a campus-wide workplace sales ban on sugar-sweetened beverages (SSBs) combined with a randomized trial of a brief motivational intervention among 214 frequent SSB consumers. At follow-up, daily SSB intake decreased significantly across the overall cohort by 48.6% (from 1050 mL to 540 mL per day). Furthermore, participants randomized to receive the brief motivational intervention in addition to the sales ban achieved substantially larger reductions in SSB consumption (mean reduction of 762 mL / 25.4 fl oz) compared to those exposed to the sales ban alone (mean reduction of 246 mL / 8.2 fl oz).
Scrolling on social media activates the brain's reward pathways by triggering a dopamine release.
"scrolling on the internet has that rewarding, that dopamine hit. All the people who've studied social media and how our brains respond, it's pretty startling." (said at 1:32:32)
Functional neuroimaging and neurophysiological studies confirm that social media use and receiving or delivering digital social feedback (such as 'likes' or novel content while scrolling) activate core regions of the brain's mesocorticolimbic dopaminergic reward pathway, including the ventral striatum, nucleus accumbens, and ventral tegmental area (VTA). Systematic reviews of fMRI studies indicate that both passive exposure to social media cues and active engagement recruit the same striatal reward circuitry that mediates reinforcement learning and incentive salience.
- supports: What the brain 'Likes': neural correlates of providing feedback on social media. (Social cognitive and affective neuroscience 2018) · cited 203x in the literature
"The experience of providing Likes to others on social media related to activation in brain circuity implicated in reward, including the striatum and ventral tegmental area, regions also implicated in the experience of receiving Likes from others." (abstract, results, passage verified)
pubmedfull study (doi) - supports: A Systematic Review of Structural and Functional MRI Studies Investigating Social Networki… (Brain sciences 2023) · cited 30x in the literature
"Regular SNS use behaviours appear to recruit regions involved in the mentalising network, the self-referential cognition network, the salience network, the reward network and the default mode network." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The Effects of Social Feedback Through the "Like" Feature on Brain Activity: A Systematic … (Healthcare (Basel, Switzerland) 2025) · cited 14x in the literature
"The review included 11 studies with 504 participants, identifying key brain structures such as the amygdala, ventromedial prefrontal cortex (vmPFC), and ventral striatum involved in reward processing. Positive feedback ("likes") activates areas like the nucleus accumbens (NACC), vmPFC, and amygdala, with NACC correlating with increased SM use intensity." (abstract, results, passage verified)
pubmedfull study (doi)
Research from Leonard Epstein's lab demonstrates that episodic future thinking manipulations, such as listening to recordings about future goals while ordering fast food in shopping malls, can influence how much people eat.
"These exercises where you transport yourself in time to times where you're at future health goals or future other events, and then using that to help inform your decision now, these manipulations from Leonard Epstein's lab have shown some effectiveness in changing eating behavior. They've had people listening to recordings of themselves talking about future goals while ordering food, fast food, in like food courts in shopping malls, and they've found that it can influence how much they eat." (said at 1:34:25)
Research conducted by Leonard Epstein and colleagues demonstrated that smartphone-delivered episodic future thinking (EFT) cues in a real-world setting (a public food court) significantly reduced total calorie and fat intake compared to control episodic recent thinking cues in overweight and obese individuals.
Fact-checked episodes
Publications
- Changes in Wearable Sleep Technology Metrics During Hypoglossal Nerve Stimulation Uptitration.The Laryngoscope 2026 · CEBM Level 4
- Outcomes from a combined cognitive behavioral therapy for insomnia (CBT-I) and sleep-related medication and substance use reduction treatment.Sleep medicine 2026 · CEBM Level 3
- Psychometric properties and predictive validity of Brazilian reward-based eating drive scale.Journal of health psychology 2026 · CEBM Level 4
- Sleep and temperature data from wearable devices support noninvasive detection of diabetes mellitus in a large-scale, retrospective analysis.Communications medicine 2026 · CEBM Level 3
- Age-related patterns in distal skin temperature during naps.Sleep 2026 · CEBM Level 3
- Heated yoga thaws depression: A dose-response analysis from a randomized controlled trial.Journal of affective disorders 2026 · CEBM Level 2
- Whole-blood transcriptomic response to whole-body hyperthermia in participants with major depressive disorder.Brain, behavior, & immunity - health 2026 · CEBM Level 2
- Wearable-derived skin temperature dynamics during sleep reveal cardiovascular perfusion deficits through mechanistic modeling.NPJ digital medicine 2026 · CEBM Level 3
- Daily social resources as a buffer against stress eating and its consequences.Health psychology : official journal of the Division of Health Psychology, American Psychological Association 2025 · CEBM Level 3
- Development and validation of a brief form of the Anticipated Effects of Food Scale.Appetite 2025 · CEBM Level 4
- Corrigendum to "The antidepressant effect of whole-body hyperthermia is associated with the classical interleukin-6 signaling pathway" [Brain Behav. Immunity 119 (2024) 801-806].Brain, behavior, and immunity 2025 · CEBM Level 5
- Sex Differences in the Variability of Physical Activity Measurements Across Multiple Timescales Recorded by a Wearable Device: Observational Retrospective Cohort Study.Journal of medical Internet research 2025 · CEBM Level 3
- Testing the Impact of Intensive, Longitudinal Sampling on Assessments of Statistical Power and Effect Size Within a Heterogeneous Human Population: Natural Experiment Using Change in Heart Rate on Weekends as a Surrogate Intervention.Journal of medical Internet research 2025 · CEBM Level 3
- Treating major depressive disorder with an integrated mind-body intervention: Whole-body hyperthermia and cognitive behavioral therapy, a case report.Advances in integrative medicine 2025 · CEBM Level 4
- A Randomized Trial Testing a Novel Mind and Body Intervention for Depression: Cognitive Behavioral Therapy (CBT) and Whole-Body Hyperthermia (WBH).Global advances in integrative medicine and health 2025 · CEBM Level 2
- A randomized controlled pilot trial of low and high arousal resilience interventions for depressive symptoms.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine 2025 · CEBM Level 2
- Elevated body temperature is associated with depressive symptoms: results from the TemPredict Study.Scientific reports 2024 · CEBM Level 4
- Utilizing Wearable Device Data for Syndromic Surveillance: A Fever Detection Approach.Sensors (Basel, Switzerland) 2024 · CEBM Level 4
- The antidepressant effect of whole-body hyperthermia is associated with the classical interleukin-6 signaling pathway.Brain, behavior, and immunity 2024 · CEBM Level 2
- Author Correction: Elevated body temperature is associated with depressive symptoms: results from the TemPredict Study.Scientific reports 2024 · CEBM Level 4
- Feasibility and acceptability of an integrated mind-body intervention for depression: whole-body hyperthermia (WBH) and cognitive behavioral therapy (CBT).International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2024 · CEBM Level 4
- COVID-19 Vaccine Side Effects and Long-Term Neutralizing Antibody Response : A Prospective Cohort Study.Annals of internal medicine 2024 · CEBM Level 3
- Five million nights: temporal dynamics in human sleep phenotypes.NPJ digital medicine 2024 · CEBM Level 3
- Information theory reveals physiological manifestations of COVID-19 that correlate with symptom density of illness.Frontiers in network physiology 2024 · CEBM Level 4
- Participant Experiences from a Randomized Controlled Trial of Heated Yoga for Depression.International journal of yoga therapy 2024 · CEBM Level 4
- A randomized controlled clinical trial of a Wim Hof Method intervention in women with high depressive symptoms.Comprehensive psychoneuroendocrinology 2024 · CEBM Level 2
- Impact of digital meditation on work stress and health outcomes among adults with overweight: A randomized controlled trial.PloS one 2023 · CEBM Level 2
- Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study.Scientific reports 2023 · CEBM Level 3
- Psychological Support Strategies for Adults With Type 2 Diabetes in a Very Low-Carbohydrate Web-Based Program: Randomized Controlled Trial.JMIR diabetes 2023 · CEBM Level 2
- Controlled trial of a workplace sales ban on sugar-sweetened beverages.Public health nutrition 2023 · CEBM Level 3
- Protocol for a randomized controlled trial comparing a very low-carbohydrate diet or moderate-carbohydrate plate-method diet for type 2 diabetes: the LEGEND (Lifestyle Education about Nutrition for Diabetes) trial.Trials 2023 · CEBM Level 5
- Correction: Treating binge eating and food addiction symptoms with low-carbohydrate Ketogenic diets: a case series.Journal of eating disorders 2023 · CEBM Level 4
- The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response.medRxiv : the preprint server for health sciences 2023 · CEBM Level 3
- Assessing Adherence to Multi-Modal Oura Ring Wearables From COVID-19 Detection Among Healthcare Workers.Cureus 2023 · CEBM Level 3
- A Randomized Controlled Trial of Community-Delivered Heated Hatha Yoga for Moderate-to-Severe Depression.The Journal of clinical psychiatry 2023 · CEBM Level 2
- Variability of temperature measurements recorded by a wearable device by biological sex.Biology of sex differences 2023 · CEBM Level 3
- Correction: Variability of temperature measurements recorded by a wearable device by biological sex.Biology of sex differences 2023 · CEBM Level 3
- Metrics from Wearable Devices as Candidate Predictors of Antibody Response Following Vaccination against COVID-19: Data from the Second TemPredict Study.Vaccines 2022 · CEBM Level 3
- Detection of COVID-19 using multimodal data from a wearable device: results from the first TemPredict Study.Scientific reports 2022 · CEBM Level 3
- Author Correction: Feasibility of continuous fever monitoring using wearable devices.Scientific reports 2022 · CEBM Level 5
- Author Correction: Detection of COVID-19 using multimodal data from a wearable device: results from the first TemPredict Study.Scientific reports 2022 · CEBM Level 3
- Association of Food Insecurity and Food Addiction Symptoms: A Secondary Analysis of Two Samples of Low-Income Female Adults.Journal of the Academy of Nutrition and Dietetics 2022 · CEBM Level 4
- Effects of a Mindfulness-Based Weight Loss Intervention on Long-Term Psychological Well-Being Among Adults with Obesity: Secondary Analyses from the Supporting Health by Integrating Nutrition and Exercise (SHINE) Trial.Mindfulness 2022 · CEBM Level 2
- Methods for detecting probable COVID-19 cases from large-scale survey data also reveal probable sex differences in symptom profiles.Frontiers in big data 2022 · CEBM Level 3
- A Pilot Study Comparing the Effects of Consuming 100% Orange Juice or Sucrose-Sweetened Beverage on Risk Factors for Cardiometabolic Disease in Women.Nutrients 2021 · CEBM Level 2
- A Brief Motivational Intervention Differentially Reduces Sugar-sweetened Beverage (SSB) Consumption.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine 2021 · CEBM Level 2
- Longer Leukocyte Telomere Length Predicts Stronger Response to a Workplace Sugar-Sweetened Beverage Sales Ban: An Exploratory Study.Current developments in nutrition 2021 · CEBM Level 3
- Negative Mood and Food Craving Strength Among Women with Overweight: Implications for Targeting Mechanisms Using a Mindful Eating Intervention.Mindfulness 2021 · CEBM Level 4
- Feasibility and acceptability of a Whole-Body hyperthermia (WBH) protocol.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2021 · CEBM Level 4
- Association of a Workplace Sales Ban on Sugar-Sweetened Beverages With Employee Consumption of Sugar-Sweetened Beverages and Health.JAMA internal medicine 2020 · CEBM Level 2
- Do stress eating or compulsive eating influence metabolic health in a mindfulness-based weight loss intervention?Health psychology : official journal of the Division of Health Psychology, American Psychological Association 2020 · CEBM Level 3
- Correction: Examining the Effects of Mindful Eating Training on Adherence to a Carbohydrate-Restricted Diet in Patients With Type 2 Diabetes (the DELISH Study): Protocol for a Randomized Controlled Trial.JMIR research protocols 2020 · CEBM Level 5
- Treating binge eating and food addiction symptoms with low-carbohydrate Ketogenic diets: a case series.Journal of eating disorders 2020 · CEBM Level 4
- Intervention Enhancement Strategies Among Adults With Type 2 Diabetes in a Very Low-Carbohydrate Web-Based Program: Evaluating the Impact With a Randomized Trial.JMIR diabetes 2020 · CEBM Level 2
- Feasibility of continuous fever monitoring using wearable devices.Scientific reports 2020 · CEBM Level 3
- Examining the Effects of Mindful Eating Training on Adherence to a Carbohydrate-Restricted Diet in Patients With Type 2 Diabetes (the DELISH Study): Protocol for a Randomized Controlled Trial.JMIR research protocols 2019 · CEBM Level 5
- Stress resilience: Narrative identity may buffer the longitudinal effects of chronic caregiving stress on mental health and telomere shortening.Brain, behavior, and immunity 2019 · CEBM Level 3
- Rapid Assessment of Reward-Related Eating: The RED-X5.Obesity (Silver Spring, Md.) 2019 · CEBM Level 4
- The burden of being poor: Stress at the belly of the matter.Brain, behavior, and immunity 2019 · CEBM Level 5
- Sweet cognition: The differential effects of glucose consumption on attentional food bias in individuals of lean and obese status.Physiology & behavior 2019 · CEBM Level 3
- Maternal caregivers have confluence of altered cortisol, high reward-driven eating, and worse metabolic health.PloS one 2019 · CEBM Level 3
- Correction: Maternal caregivers have confluence of altered cortisol, high reward-driven eating, and worse metabolic health.PloS one 2019 · CEBM Level 5
- Lipid findings from the Diabetes Education to Lower Insulin, Sugars, and Hunger (DELISH) Study.Nutrition & metabolism 2019 · CEBM Level 4
- Correction to: Lipid findings from the Diabetes Education to Lower Insulin, Sugars, and Hunger (DELISH) Study.Nutrition & metabolism 2019 · CEBM Level 5
- A Randomized Controlled Trial of a Mindfulness-Based Weight Loss Intervention on Cardiovascular Reactivity to Social-Evaluative Threat Among Adults with Obesity.Mindfulness 2019 · CEBM Level 2
- Testing a mobile mindful eating intervention targeting craving-related eating: feasibility and proof of concept.Journal of behavioral medicine 2018 · CEBM Level 4
- Comfort Eating and All-Cause Mortality in the US Health and Retirement Study.International journal of behavioral medicine 2018 · CEBM Level 3
- Chronic Stress and Impulsive Risk-Taking Predict Increases in Visceral Fat over 18 Months.Obesity (Silver Spring, Md.) 2018 · CEBM Level 3
- Authors' Reply: Comment on "An Online Intervention Comparing a Very Low-Carbohydrate Ketogenic Diet and Lifestyle Recommendations Versus a Plate Method Diet in Overweight Individuals With Type 2 Diabetes: A Randomized Controlled Trial".Journal of medical Internet research 2018 · CEBM Level 5
- Weight Loss Maintenance and Cellular Aging in the Supporting Health Through Nutrition and Exercise Study.Psychosomatic medicine 2018 · CEBM Level 2
- Can Mindfulness Address Maladaptive Eating Behaviors? Why Traditional Diet Plans Fail and How New Mechanistic Insights May Lead to Novel Interventions.Frontiers in psychology 2018 · CEBM Level 5
- Impact of a Mindfulness-Based Weight-Loss Intervention on Sleep Quality Among Adults with Obesity: Data from the SHINE Randomized Controlled Trial.Journal of alternative and complementary medicine (New York, N.Y.) 2017 · CEBM Level 2
- An Online Intervention Comparing a Very Low-Carbohydrate Ketogenic Diet and Lifestyle Recommendations Versus a Plate Method Diet in Overweight Individuals With Type 2 Diabetes: A Randomized Controlled Trial.Journal of medical Internet research 2017 · CEBM Level 2
- Improving Assessment of the Spectrum of Reward-Related Eating: The RED-13.Frontiers in psychology 2017 · CEBM Level 4
- The contemptuous separation: Facial expressions of emotion and breakups in young adulthood.Personal Relationships 2017 · CEBM Level 3
- Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes.Nutrition & diabetes 2017 · CEBM Level 2
- Effects of a mindfulness-based intervention on mindful eating, sweets consumption, and fasting glucose levels in obese adults: data from the SHINE randomized controlled trial.Journal of behavioral medicine 2016 · CEBM Level 2
- Reduced reward-driven eating accounts for the impact of a mindfulness-based diet and exercise intervention on weight loss: Data from the SHINE randomized controlled trial.Appetite 2016 · CEBM Level 2
- Excessive Sugar Consumption May Be a Difficult Habit to Break: A View From the Brain and Body.The Journal of clinical endocrinology and metabolism 2015 · CEBM Level 2
- Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial.Appetite 2015 · CEBM Level 2
- Putting the brakes on the "drive to eat": Pilot effects of naltrexone and reward-based eating on food cravings among obese women.Eating behaviors 2015 · CEBM Level 2
- Prospective associations among approach coping, alcohol misuse and psychiatric symptoms among veterans receiving a brief alcohol intervention.Journal of substance abuse treatment 2014 · CEBM Level 3
- The reward-based eating drive scale: a self-report index of reward-based eating.PloS one 2014 · CEBM Level 4
- Sleep complaints predict increases in resting blood pressure following marital separation.Health psychology : official journal of the Division of Health Psychology, American Psychological Association 2014 · CEBM Level 3
- Expressive Writing Can Impede Emotional Recovery Following Marital Separation.Clinical psychological science : a journal of the Association for Psychological Science 2013 · CEBM Level 2
- Facing a breakup: Electromyographic responses moderate self-concept recovery following a romantic separation.Personal Relationships 2012 · CEBM Level 3